Board Renewal / Composition Update
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has announced updates regarding its Board composition and renewal initiatives. Dr. David Atkins will join the Board as Managing Director immediately, while Dr. Trevor Lockett and Mr. Lou Panaccio will retire at the upcoming Annual General Meeting. Mr. Otto Buttula will also step down as Chair before the end of the calendar year, with ongoing discussions for new directors including a new Chair. The company acknowledges the contributions of retiring directors and expresses gratitude for their service since the company's inception.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Platform Expansion - Gastric Cancer Diagnostic Test Update
- Product and Market Update - Phase 2 Milestone
- Jun 24 Quarterly Activities Report and Appendix 4C
- Mar24 Quarterly Activities Report and Appendix 4C
- Dr David Atkins appointed Chief Executive Officer of Rhythm
Later from Rhythm Biosciences
- 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
- Receipt of Research & Development Tax Incentive
- Strong Demand in Share Placement to Raise $3.5 million
- Market Update - All End of CY24 Milestones Attained
- Pause in Trading
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences